Back to mobile site

More on MNPR

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (9.4 Score)

Upcoming Events

- Earnings (8/6/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Monopar Therapeutics (NQ:MNPR)
Delayed: 59.77 +0.67 (1.13%)
Prev. Close $59.10  
Open$59.41 
52 Wk High$ 
52 Wk Low$ 
Day High$61.17 
Day Low$59.06 
P/E N/A  
EPS$ 
Volume154,407 


Jun 2, 2026 06:58 AM H.C. Wainwright Reiterates Buy Rating on Monopar Therapeutics (MNPR)
Jun 1, 2026 07:00 AM Monopar presents Phase 2 data showing ALXN1840 benefits for Wilson disease
Jun 1, 2026 07:00 AM Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
May 29, 2026 04:57 PM Form 8-K Monopar Therapeutics For: May 29
May 19, 2026 05:33 PM Monopar study shows ALXN1840 improves copper balance in Wilson disease
May 19, 2026 05:33 PM Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
May 19, 2026 05:27 PM Form 8-K Monopar Therapeutics For: May 19
May 15, 2026 01:26 PM Form SCHEDULE 13G Monopar Therapeutics Filed by: Saturn V Capital Management LP
May 15, 2026 06:12 AM Monopar Therapeutics (MNPR) Misses Q1 EPS by 46c
May 14, 2026 02:01 PM Form 10-Q Monopar Therapeutics For: Mar 31
View All Articles

Entities mentioned with MNPR

View All Entities